Money pours into health care ETFs at fastest pace since 2008

Mar 6, 2014 @ 9:11 am

+ Zoom

Money is flooding into exchange-traded funds focused on health care at the fastest rate in at least six years, driven by booming biotechnology and pharmaceutical sectors bringing new products to market.

In 2014, 51% of money flowing into U.S. sector- focused ETFs, or $4.06 billion through Feb. 28, was for health-care funds, according to data compiled by Bloomberg. That's more than two-thirds of the total deposits the funds attracted in all of 2013, and a greater share of total ETF contributions than any time since at least 2008.

“People thought drug development was dead and all there was was a patent cliff,” Doug Foreman, chief investment officer at Kayne Anderson Rudnick Investment Management, whose firm oversees about $9 billion, said referring to the loss of exclusivity for top-selling brand-name medicines. “There isn't a day that goes by that some company doesn't report positive results from a trial and the stock is up 100 percent.”

Exchange-traded funds are securities that track an index or basket of stocks or bonds in a given market or industry sector. They can be easily traded and come with low costs. Inflows to U.S. ETFs more than tripled to $183 billion last year from 2004, according to data compiled by Bloomberg.

This year also is the health-care sector's highest share of ETF inflows since President Barack Obama took office and debate began in 2009 over the Patient Protection and Affordable Care Act, Obama's signature health-care overhaul. After the law was signed in 2010, health-care ETFs saw $944.9 million leave, and health was the worst performing of 12 ETF sectors.


Concern that the law known as Obamacare would damage the sector — which helped drive down health stocks in 2010 — is largely over, said Les Funtleyder, a longtime heath-sector investor and analyst who is a consulting partner at Bluecloud Healthcare. The firm doesn't have an health-care ETF investments.

“The ACA has kind of come and gone,” he said. “It's been implemented and nothing bad has happened to the companies by and large.”

The biggest health-care ETFs are dominated by pharmaceutical and biotechnology drug stocks, which are enjoying a boom. Among the three funds with the biggest inflows this year, nine of the top 10 holdings in each fund are drug and biotech companies, according to data compiled by Bloomberg.

The Standard & Poor's 500 Biotechnology Index gained 74% last year compared with a 30% increase in the entire S&P 500. Pharmaceuticals and biotechnology companies jumped 9.3% this year as a group, beating all other 23 industries in the S&P. Institutional investors who don't specialize are using ETFs to get in on that rise, according to Ravi Mehrotra, an analyst at Credit Suisse Group AG.

“The central key reason for the biotech sector's stellar performance since 2011 has been generalist inflows,” he said in a Feb. 27 note to clients.

The funds offer an easy way into drug and biotechnology stocks. “If you're an institutional investor, and you're not a health-care specialist, and the sector is outperforming, the fastest way to get to an equal-weight or overweight exposure is through ETFs,” Mr. Funtleyder said.

Biotechnology companies are bringing new medicines to market, while pharmaceutical companies have managed to move past the loss of top products from patent expirations.

Gilead Sciences Inc., a biotechnology company that is the world's biggest maker of AIDS medicines, last year gained U.S. approval of a liver disease drug that may become one of the biggest sellers in history. The company more than doubled in value in 2013.

The Nasdaq Biotechnology Index has gained 18% this year as InterMune Inc. more than doubled to lead the advance. The shares of the company soared 171% on Feb. 25 after its drug pirfenidone, used to treat a fatal lung disease, met goals of a study expected to support U.S. approval.

“In an environment where economic growth is relatively scarce, people are willing to pay a higher price for that growth,” James Abate, who oversees about $1 billion as chief investment officer at Centre Asset Management, which owns shares of Gilead but doesn't have investments in any health-care ETFs. “And health-care companies, by nature of their lack of sensitivity to economic ups and downs, can continue to deliver.”

Pfizer Inc., the world's biggest drugmaker, has maintained earnings excluding certain items at $2.23 a share in 2010 to $2.22 last year, even as sales fell 23% over that period. It has done so by buying back shares and introducing two new potential blockbuster drugs.

“The Pfizers, Mercks and Lillys of the world, those have been doubted for years,” said Tony Scherrer, director of research at Smead Capital Management Inc., referring Merck & Co. and Eli Lilly & Co. “The patent cliff issues are real, but the big pharmas are managing through that really well and they have pipelines that look better than people were thinking,” he said. The fund manages $861 million though it doesn't have health-care ETF investments.

(Bloomberg News)


What do you think?

View comments

Recommended for you

Featured video


Stephanie Bogan: What's really holding advisers back from achieving their goals

The only thing holding financial advisers back from accomplishing what they want is the assumptions they're making, according to Stephanie Bogan, founder of Educe Inc.

Latest news & opinion

Fidelity wins arb case against wine mogul but earns a rebuke from Finra

In the case of investor Peter Deutsch, Fidelity doesn't have to pay any compensation, but regulator said firm put its interests ahead of his.

Plaintiffs win in Tibble vs. Edison 401(k) fee case

After a decade of activity around the lawsuit, including a hearing before the U.S. Supreme Court, judge rules a prudent fiduciary would have invested in institutional shares.

Advisers get more breathing room to make Form ADV changes

RIAs can enter '0' in some new parts of the document before their annual filing next year.

Since banking scandal, Wells Fargo advisers with more than $19.2 billion leave firm

Despite a trying year, the firm has said it will sweeten signing bonuses for veteran advisers.

Is LPL's deal sweet enough for NPH's 3,200 reps and advisers?

They will have to decide if the signing package they are being offered by LPL makes sense. A lot is hanging in the balance.


Subscribe and Save 60%

Premium Access
Print + Digital

Learn more
Subscribe to Print